JPH0358998A - 高純度タンパク質の安定化 - Google Patents

高純度タンパク質の安定化

Info

Publication number: JPH0358998A
Authority: JP; Japan
Prior art keywords: protein; dextran; added; factor; albumin
Prior art date: 1989-07-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2190898A

Other languages

English (en)

Japanese (ja)

Inventor

Michael H Coan

マイケル・エイチ・コーン

Vivian W Lee

ビビアン・ダブリユー・リー

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Corp

Original Assignee

Miles Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-24

Filing date

1990-07-20

Publication date

1991-03-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23517903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0358998(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-07-20 Application filed by Miles Inc filed Critical Miles Inc

1991-03-14 Publication of JPH0358998A publication Critical patent/JPH0358998A/ja

Status Pending legal-status Critical Current

Links

102000004169 proteins and genes Human genes 0.000 title claims abstract description 54
108090000623 proteins and genes Proteins 0.000 title claims abstract description 54
230000006641 stabilisation Effects 0.000 title description 7
238000011105 stabilization Methods 0.000 title description 7
150000001720 carbohydrates Chemical class 0.000 claims abstract description 26
238000004108 freeze drying Methods 0.000 claims abstract description 16
239000003381 stabilizer Substances 0.000 claims description 33
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 28
235000014633 carbohydrates Nutrition 0.000 claims description 23
238000000034 method Methods 0.000 claims description 21
230000000694 effects Effects 0.000 claims description 18
239000000203 mixture Substances 0.000 claims description 15
239000004471 Glycine Substances 0.000 claims description 14
239000000243 solution Substances 0.000 claims description 12
150000005846 sugar alcohols Chemical class 0.000 claims description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
229920000642 polymer Polymers 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
239000008103 glucose Substances 0.000 claims description 4
239000011780 sodium chloride Substances 0.000 claims description 4
238000001042 affinity chromatography Methods 0.000 claims description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
239000001110 calcium chloride Substances 0.000 claims description 2
229910001628 calcium chloride Inorganic materials 0.000 claims description 2
238000011210 chromatographic step Methods 0.000 claims description 2
239000012045 crude solution Substances 0.000 claims description 2
238000004255 ion exchange chromatography Methods 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
230000004952 protein activity Effects 0.000 claims description 2
238000001542 size-exclusion chromatography Methods 0.000 claims description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract description 27
229930195725 Mannitol Natural products 0.000 abstract description 27
239000000594 mannitol Substances 0.000 abstract description 27
235000010355 mannitol Nutrition 0.000 abstract description 27
238000000746 purification Methods 0.000 abstract description 13
FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 abstract description 8
229940119743 dextran 70 Drugs 0.000 abstract description 8
102000001690 Factor VIII Human genes 0.000 abstract 1
108010054218 Factor VIII Proteins 0.000 abstract 1
229960000301 factor viii Drugs 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 44
229920002307 Dextran Polymers 0.000 description 34
229960002086 dextran Drugs 0.000 description 33
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 33
102000009027 Albumins Human genes 0.000 description 28
108010088751 Albumins Proteins 0.000 description 28
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 23
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 23
239000000600 sorbitol Substances 0.000 description 23
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
238000002474 experimental method Methods 0.000 description 13
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
238000011084 recovery Methods 0.000 description 11
238000000108 ultra-filtration Methods 0.000 description 9
108010094028 Prothrombin Proteins 0.000 description 7
239000000872 buffer Substances 0.000 description 7
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 7
150000001875 compounds Chemical class 0.000 description 6
238000010438 heat treatment Methods 0.000 description 6
230000004071 biological effect Effects 0.000 description 5
238000002523 gelfiltration Methods 0.000 description 5
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
238000011026 diafiltration Methods 0.000 description 4
229920001542 oligosaccharide Polymers 0.000 description 4
150000002482 oligosaccharides Chemical class 0.000 description 4
239000000047 product Substances 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
238000010828 elution Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000000178 monomer Substances 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000000087 stabilizing effect Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
229920002271 DEAE-Sepharose Polymers 0.000 description 2
102100031939 Erythropoietin Human genes 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000012531 culture fluid Substances 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000012538 diafiltration buffer Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000011067 equilibration Methods 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
150000002772 monosaccharides Chemical class 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000007858 starting material Substances 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
101100130497 Drosophila melanogaster Mical gene Proteins 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
206010072104 Fructose intolerance Diseases 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
206010019878 Hereditary fructose intolerance Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
229920001612 Hydroxyethyl starch Polymers 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
238000011033 desalting Methods 0.000 description 1
229940041984 dextran 1 Drugs 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
239000000499 gel Substances 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
-1 glycine Chemical class 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
229940050526 hydroxyethylstarch Drugs 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
229910017053 inorganic salt Inorganic materials 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940006899 methylcellulose 10 mg/ml Drugs 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
229940086870 plasbumin Drugs 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229920000867 polyelectrolyte Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
238000009877 rendering Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000011435 rock Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000010257 thawing Methods 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
239000002023 wood Substances 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP2190898A 1989-07-24 1990-07-20 高純度タンパク質の安定化 Pending JPH0358998A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38458489A	1989-07-24	1989-07-24
US384584		1989-07-24

Publications (1)

Publication Number	Publication Date
JPH0358998A true JPH0358998A (ja)	1991-03-14

Family

ID=23517903

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2190898A Pending JPH0358998A (ja)	1989-07-24	1990-07-20	高純度タンパク質の安定化

Country Status (8)

Country	Link
EP (1)	EP0410207B1 (fr)
JP (1)	JPH0358998A (fr)
AT (1)	ATE148165T1 (fr)
CA (1)	CA2021452A1 (fr)
DE (1)	DE69029765T2 (fr)
DK (1)	DK0410207T3 (fr)
ES (1)	ES2097120T3 (fr)
GR (1)	GR3022614T3 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20030060660A (ko) *	2002-01-10	2003-07-16	손정일	앞/뒷면 구별 없는 양면 양말
JP2008501639A (ja) *	2004-04-23	2008-01-24	ノベシンリミテッド	タンパク質を安定化、保護及び可溶化させるための方法及びキット
JP2014516515A (ja) *	2011-04-29	2014-07-17	オンコリティクスバイオテク，インコーポレーテッド	ゲル浸透クロマトグラフィーを使用してウイルスを精製する方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2966592B2 (ja) *	1991-07-20	1999-10-25	萩原義秀	安定化されたヒトモノクローナル抗体製剤
US6165467A (en) *	1991-07-20	2000-12-26	Yoshihide Hagiwara	Stabilized human monoclonal antibody preparation
US6270723B1 (en) *	1998-06-15	2001-08-07	Bbi Bioseq, Inc.	Rapid cryobaric sterilization and vaccine preparation
DK1820516T3 (da)	1999-02-22	2013-10-28	Univ Connecticut	Nye albuminfrie faktor VIII-præparater
EP1336107B1 (fr)	1999-07-14	2009-01-07	Spectral Diagnostics Inc.	Preparation de spheres pour essais diagnostics
EP1343518B1 (fr)	2000-11-07	2009-07-22	Novartis Vaccines and Diagnostics, Inc.	Compositions d'interferon stabilisees
US6887462B2 (en)	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
WO2003014339A2 (fr) *	2001-08-07	2003-02-20	Novozymes, A/S	Hydrates de carbones et polyols permettant de dissoudre les cristaux de proteines
CN1703233A (zh) *	2002-07-12	2005-11-30	米德列斯公司	防止蛋白氧化降解的方法和组合物
EP1749018B1 (fr) *	2004-04-23	2014-10-22	Expedeon Limited	Procedes et kits pour stabiliser, proteger et solubiliser des proteines
CA2675602A1 (fr) *	2007-02-16	2008-08-21	Wyeth	Formulations de proteine contenant du sorbitol
CN102026621A (zh)	2008-05-15	2011-04-20	巴克斯特国际公司	稳定的药物制剂
MX339060B (es)	2008-11-07	2016-05-09	Baxter Int	Formulaciones del factor viii.
EP2646051A4 (fr)	2010-12-02	2014-05-28	Oncolytics Biotech Inc	Formulations de virus liquides
MX349294B (es)	2010-12-02	2017-07-21	Oncolytics Biotech Inc	Formulaciones virales liofilizadas.
CN106687126B (zh)	2014-08-04	2020-07-28	杰特有限公司	因子viii制剂
WO2021001522A1 (fr)	2019-07-04	2021-01-07	CSL Behring Lengnau AG	Facteur de von willebrand (vwf) tronqué pour augmenter la stabilité in vitro du facteur viii de coagulation
JP2025512143A (ja)	2020-11-09	2025-04-17	武田薬品工業株式会社	酸化ケイ素吸着を使用する血漿からのｆｖｉｉｉの精製

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4743680A (en) *	1985-02-01	1988-05-10	New York University	Method for purifying antihemophilic factor
JPH0387173A (ja) *	1987-09-10	1991-04-11	Teijin Ltd	ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
CA1329760C (fr) *	1987-10-29	1994-05-24	Ted C. K. Lee	Formulation de plasma et de proteines recombinantes dans des milieux a grande force ionique

1990
- 1990-07-11 EP EP90113210A patent/EP0410207B1/fr not_active Revoked
- 1990-07-11 ES ES90113210T patent/ES2097120T3/es not_active Expired - Lifetime
- 1990-07-11 AT AT90113210T patent/ATE148165T1/de active
- 1990-07-11 DE DE69029765T patent/DE69029765T2/de not_active Revoked
- 1990-07-11 DK DK90113210.0T patent/DK0410207T3/da active
- 1990-07-18 CA CA002021452A patent/CA2021452A1/fr not_active Abandoned
- 1990-07-20 JP JP2190898A patent/JPH0358998A/ja active Pending
1997
- 1997-02-19 GR GR970400303T patent/GR3022614T3/el unknown

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20030060660A (ko) *	2002-01-10	2003-07-16	손정일	앞/뒷면 구별 없는 양면 양말
JP2008501639A (ja) *	2004-04-23	2008-01-24	ノベシンリミテッド	タンパク質を安定化、保護及び可溶化させるための方法及びキット
JP2014516515A (ja) *	2011-04-29	2014-07-17	オンコリティクスバイオテク，インコーポレーテッド	ゲル浸透クロマトグラフィーを使用してウイルスを精製する方法

Also Published As

Publication number	Publication date
DK0410207T3 (da)	1997-07-14
DE69029765T2 (de)	1997-05-15
GR3022614T3 (en)	1997-05-31
ES2097120T3 (es)	1997-04-01
EP0410207B1 (fr)	1997-01-22
ATE148165T1 (de)	1997-02-15
EP0410207A2 (fr)	1991-01-30
CA2021452A1 (fr)	1991-01-25
DE69029765D1 (de)	1997-03-06
EP0410207A3 (en)	1992-01-15

Publication	Publication Date	Title
JPH0358998A (ja)	1991-03-14	高純度タンパク質の安定化
EP0772452B1 (fr)	2002-08-28	Formulation pharmaceutique servant a effectuer l'administration sous-cutanee, intramusculaire ou intradermique de facteur viii
EP0627924B1 (fr)	2000-12-27	Composition comprenant une formulation d'un facteur de coagulation viii, procede pour sa preparation et utilisation d'un agent tensioactif comme stabilisateur
CA2161350C (fr)	2007-10-30	Solution aqueuse de facteur viii a teneur reduite en oxygene
JPS597693B2 (ja)	1984-02-20	抗トロンビン製剤及びその製法
CA2216098C (fr)	2011-08-23	Formulation de protein comprenant le facteur de coagulation viii ou ix dans une solution aqueuse
JP3537440B2 (ja)	2004-06-14	可溶性トロンボモジュリンを長期保存安定化させる方法
WO1996041817A1 (fr)	1996-12-27	Fraction peptidique de collagene et ses utilisations
EP0954326B1 (fr)	2005-06-29	Procede d'inactivation de virus dans des proteines sanguines lyophilisees
AU2009240026B2 (en)	2014-05-29	Dry transglutaminase composition
JPH03218399A (ja)	1991-09-25	尿由来の抗血液疑固物質、その製法およびそれを含有する医薬組成物
RU2136294C1 (ru)	1999-09-10	Композиция, содержащая препарат коагуляционного фактора viii, способ ее получения и применение поверхностно-активного вещества в качестве стабилизатора
KR100373882B1 (ko)	2003-08-02	인자ⅷ의피하,근내또는피내투여용약제학적제형
EP4322918A1 (fr)	2024-02-21	Composition liquide comprenant un complexe de facteur viii ou facteur viii/facteur de von willebrand
MXPA96004455A (en)	1997-12-01	Pharmaceutical formulation for administracionsubcutanea, intramuscular or intradermica of factorviii or factor

JPH0358998A - 高純度タンパク質の安定化 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=23517903

Family Applications (1)

Country Status (8)

Cited By (3)

Families Citing this family (18)

Family Cites Families (3)

Cited By (3)

Also Published As

Similar Documents